原文文献：

Alexandrou S, Lee CS, Fernandez KJ, Wiharja CE, Eshraghi L, Reeves J, Reed DA, Portman N, Phan Z, Milioli HH, Nikolic I, Cadell AL, Croucher DR, Simpson KJ, Lim E, Hickey TE, Millar EKA, Alves CL, Ditzel HJ, Caldon CE. JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer. J Exp Clin Cancer Res. 2025 Aug 19;44(1):244. doi: 10.1186/s13046-025-03466-9.